The effect of 1-furan-2-yl-3-pyridine-2-yl-propenone on pharmacokinetic parameters of warfarin

Archives of Pharmacal Research

Volumn 30, Issue 7, 2007, Pages 898-904

  Shanmugam, Srinivasan ^a   Eung, Seok Lee ^a   Tae, Cheon Jeong ^a   Chul, Soon Yong ^a   Choi, Han Gon ^a   Woo, Jong Soo ^b   Bong, Kyu Yoo ^a  

^a Yeungnam University   (South Korea)

^b Hanmi Pharmaceutical Co Ltd   (South Korea)

Author keywords

1 Furan 2 yl 3 pyridine 2 yl propenone; Cytochrome P450; Pharmacokinetics; Prothrombin time; Warfarin

Indexed keywords

EID: 34547617553     PISSN: 02536269     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02978843     Document Type: Article

References (18)

1. Belton, O., Byrne, D., Kearney, D., Leahy, A., and Fitzgerald, D., Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation, 102, 840-845 (2000).
2. Blank, J., Tucker, A., Sweatlock, J., Gasiewicz, T., and Luster, M., Alpha-Naphthoflavone antagonism of 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced murine lymphocyte ethoxyresorufin-O-deethylase activity and immunosuppression. Mol. Pharmacol., 32, 169-172 (1987).
3. Burnier, M., The safety of rofecoxib. Expert Opin. Drug Saf., 4, 491-499 (2005).
4. Clark, D., Layton, D., and Shakir S., Do some inhibitors of COX-2 increase the risk of thromboembolic events?: Linking pharmacology with pharmacoepidemiology. Drug Saf., 27, 427-456 (2004).
5. Crespi, C., Miller, V., and Penman, B., Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal. Biochem., 248, 188-90 (1997).
6. Fiorucci, S., Meli, R., Bucci, M., and Cirino, G., Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in antiinflammatory therapy? Biochem. Pharmacol., 62, 1433-1438 (2001).
7. Fosslien, E., Cardiovascular complications of non-steroidal anti-inflammatory drugs. Ann. Clin. Lab. Sci., 35, 347-385 (2005).
8. Jahng, Y., Zhao, L., Moon, Y., Basnet, A., Kim, E., Chang, H., Ju, H., Jeong, T., and Lee, E., Simple aromatic compounds containing propenone moiety show considerable dual COX/ 5-LOX inhibitory activities. Bioorg. Med. Chem. Lett., 14, 2559-2562 (2004).
9. Joffe, H., Xu, R., Johnson, F., Longtine, J., Kucher, N., and Goldhaber, S., Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb. Haemost., 91, 1123-1128 (2004)..
10. Kwan, D., Bartle, W., and Walker, S., The effects of acetaminophen on pharmacokinetics and pharmacodynamics of warfarin. J. Clin. Pharmacol., 39, 68-75 (1999).
11. Lee, E., Ju, H., Moon, T., Lee, E., Jahng, Y., Lee, S., Son, J., Baek, S., and Chang, H., Inhibition of nitric oxide and tumor necrosis factor-alpha (TNF-alpha) production by propenone compound through blockade of nuclear factor (NF)-kappa B activation in cultured murine macrophages. Biol. Pharm. Bull., 27, 617-620 (2004).
12. Lee, S., Jeon, T., Basnet, A., Jeong, H., Lee, E., and Jeong, T., Identification of 1-furan-2-yl-3-pyridin-2-yl-propenone, an antiinflammatory agent, and its metabolites in rat liver subcellular fractions. Arch. Pharm. Res., 29, 984-989 (2006).
13. Schmedtje, J., Ji, Y., Liu, W., DuBois, R., and Runge, M., Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J. Biol. Chem., 272, 601-608 (1997).
14. Shanmugam, S., Lee, E., Lee, S., Jeon, T., Yong, C., and Yoo, B., The Effect of 1-Furan-2-yl-3-pyridine-2-yl-propenone on Pharmacokinetic Parameters of Theophylline. Biol. Pharm. Bull., 29, 1282-1285 (2006).
15. Takeuchi, K., Tanaka, A., Hayashi, Y., and Yokota, A., COX inhibition and NSAID-induced gastric damage - roles in various pathogenic events. Curr. Top. Med. Chem., 5, 475-486 (2005).
16. Whelton, A., Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics. Am. J. Ther., 7, 63-74 (2000).
17. Wolfe, F., Anderson, J., Burke, T., Arguelles, L., and Pettitt, D., Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy. J. Rheumatol., 29, 467-473 (2002).
18. Yacobi, A., Masson, E., Moros, D., Ganes, D., Lapointe, C., Abolfathi, Z., LeBel, M., Golander, Y., Doepner, D., Blumberg, T., Cohen, Y., and Levitt, B., Who needs individual bioequivalence studies for narrow therapeutic index drugs? A case for warfarin. J. Clin. Pharmacol., 40, 826-835 (2000).